Pulmonx director French Glendon E. III sells $161,800 in company stock

In a recent transaction, French Glendon E. III, a director of Pulmonx Corp (NASDAQ:LUNG), sold 20,000 shares of company stock, netting a total of $161,800. The sale took place on September 12, 2024, under a prearranged trading plan.


The shares were sold at an average price of $8.09, with individual transactions occurring within a price range from $7.67 to $8.43. Following the sale, French's remaining holdings in Pulmonx Corp amount to 1,111,974 shares of common stock.


This sale was conducted in accordance with a Rule 10b5-1 trading plan, which was established by French Glendon E. III on June 10, 2024. Rule 10b5-1 plans allow company insiders to set up predetermined trading arrangements for selling stocks at a time when they are not in possession of material non-public information.


Investors interested in the detailed breakdown of sale prices for this transaction can request full information from the reporting person. The necessary details will be provided, including the number of shares sold at each price point within the specified range.


Pulmonx Corp, based in Redwood (NYSE:RWT ) City, California, is a company specializing in surgical and medical instruments and apparatus. The company's shares are traded on the NASDAQ under the ticker symbol LUNG.



In other recent news, Pulmonx Corp. has demonstrated strong financial performance with a 21% year-over-year increase in its second-quarter revenue, which surpassed both Canaccord Genuity's and consensus estimates. The company's disciplined approach to operating expenses and its successful expansion into new centers largely contributed to this achievement. Pulmonx's second-quarter earnings per share (EPS) was reported at ($0.39), proving more favorable than both Canaccord's estimate of ($0.47) and the consensus estimate of ($0.42).


In response to these results, Canaccord Genuity maintained a Buy rating on Pulmonx and increased the price target to $16.00 from the previous $15.00. Similarly, Lake Street Capital Markets initiated coverage on Pulmonx with a Buy rating, highlighting the opportunity for the stock to realign with comparable companies due to strong performance.


Despite the company's robust start to 2024 with a 30% increase in worldwide sales, management chose to reiterate its full-year 2024 guidance. This decision, according to Canaccord Genuity, reflects a conservative stance due to historical unpredictability in seasonal demand, particularly in the U.S. market. These are the recent developments that investors should take into account.
InvestingPro Insights


Amidst the recent sale of Pulmonx Corp shares by director French Glendon E. III, insights from InvestingPro provide a broader context for the company's financial health and market performance. Pulmonx Corp, which specializes in medical instruments, holds a market capitalization of approximately $329.27 million, reflecting its size and influence within the sector.


The company's Price-to-Earnings (P/E) ratio stands at -5.71, indicating that investors are willing to pay $5.71 for every dollar of losses, which can be seen as a sign of investor confidence in the company's future profitability despite current losses. Additionally, a significant metric to consider is the company's recent performance in the stock market, with a robust return of 42.58% over the last three months leading up to the end of September 2024. This could suggest a growing investor optimism around the company's prospects.


An important InvestingPro Tip to note is that Pulmonx Corp holds more cash than debt on its balance sheet, providing it with a solid financial foundation and potentially less risk for investors concerned about the company's solvency. Moreover, Pulmonx's liquid assets exceed its short-term obligations, further underlining its financial stability.


However, it's important for investors to be aware of potential challenges ahead. According to InvestingPro Tips, analysts have revised their earnings downwards for the upcoming period, and they do not anticipate the company will be profitable this year. For those interested in exploring further insights, there are additional InvestingPro Tips available for Pulmonx Corp at https://www.investing.com/pro/LUNG, which could help investors make more informed decisions.


As the company navigates through its financial year, keeping an eye on these metrics and tips from InvestingPro could provide investors with valuable information on Pulmonx Corp's performance and future potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com